In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has
been limited to the management of its symptoms and complications. Recently, the US Food
and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney
function decline in adults at risk of rapidly progressing ADPKD. Full prescribing information
approved by the FDA provides helpful guidelines but does not address practical questions
that are being raised by nephrologists, internists, and general practitioners taking care of …